Linezolid (as component of XDR-TB regimen)
Treatment for Hiv Aids Extensively Drug Resistant Tuberculosis
Typical Dosage: 600mg daily (often reduced to 300mg daily)
Effectiveness
80%
Safety Score
34%
Clinical Trials
50
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
34
DangerousModerateSafe
Treatment Details
Dosage Range
600mg daily (often reduced to 300mg daily)
Time to Effect
Contributes to sputum conversion within weeks (as part of regimen)
Treatment Duration
Typically 6-9 months (as part of regimen)
Evidence Quality
HIGHNumber Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$3,000
Monitoring:$2,000
Side Effect Mgmt:$3,000
Total Annual:$8,000
Linezolid (as component of XDR-TB regimen) Outcomes
for Hiv Aids Extensively Drug Resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+80%
Common Side Effects
Peripheral neuropathy
+60%
Myelosuppression (anemia, thrombocytopenia)
+25%
Optic neuropathy
+7%
Lactic acidosis
+5%
Gastrointestinal disturbances
+15%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov